← Back to Search

Dexamethasone for Knee Surgery

Phase 4
Waitlist Available
Research Sponsored by Rush University Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age > 18 years
Patients staying at least one night in the hospital after surgery
Must not have
Primary TKA requiring hardware removal
Current systemic fungal infection
Timeline
Screening 3 weeks
Treatment Varies
Follow Up <30 days after surgical intervention, document any readmissions to the hospital or complications that occur within 30 days from the day of surgery
Awards & highlights
Drug Has Already Been Approved
No Placebo-Only Group
Pivotal Trial

Summary

This trial is testing whether a lower dose of the steroid dexamethasone given during surgery can reduce postoperative pain and the need for opioids without increasing other complications.

Who is the study for?
This trial is for adults over 18 who are staying in the hospital at least one night after a primary total knee replacement surgery. It's not for those with inflammatory arthritis, current fungal infections, kidney or liver failure, planned same-day discharge, recent corticosteroid use, or a history of bad reactions to steroids.
What is being tested?
The study is testing three different doses of dexamethasone (16mg, 8mg/mL suspension, and 4mg) given during knee replacement surgery. The goal is to see which dose best reduces pain and opioid need after surgery while also lowering nausea/vomiting and complications.
What are the potential side effects?
Dexamethasone may cause side effects like increased blood sugar levels, higher risk of infection due to immune suppression, mood swings or sleep disturbances. Long-term use can lead to bone loss or stomach ulcers but this trial involves a single dose.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am older than 18 years.
Select...
I stayed in the hospital overnight after my surgery.
Select...
I am having or have had a total knee replacement.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I need to have hardware removed from my knee replacement.
Select...
I have a fungal infection in my body.
Select...
I am under 18 years old.
Select...
I will be discharged from the hospital on the same day of my procedure.
Select...
I have inflammatory arthritis.
Select...
I have kidney or liver failure.
Select...
I am having or have had a partial or complete knee replacement surgery.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~<30 days after surgical intervention, document any readmissions to the hospital or complications that occur within 30 days from the day of surgery
This trial's timeline: 3 weeks for screening, Varies for treatment, and <30 days after surgical intervention, document any readmissions to the hospital or complications that occur within 30 days from the day of surgery for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Opioid consumption
Secondary study objectives
Length of stay
Number of participants with complications (such as readmission to hospital) up to 30 days after surgical intervention
Postoperative Blood glucose levels and insulin use
+3 more

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

3Treatment groups
Active Control
Group I: Group 1Active Control1 Intervention
4mg intravenous dexamethasone, administered shortly after induction of anesthesia
Group II: Group 2Active Control1 Intervention
8mg intravenous dexamethasone, administered shortly after induction of anesthesia
Group III: Group 3Active Control1 Intervention
16mg intravenous dexamethasone, administered shortly after induction of anesthesia

Find a Location

Who is running the clinical trial?

Rush University Medical CenterLead Sponsor
436 Previous Clinical Trials
248,848 Total Patients Enrolled

Media Library

Group 1 Clinical Trial Eligibility Overview. Trial Name: NCT05018091 — Phase 4
Total Knee Replacement Research Study Groups: Group 1, Group 2, Group 3
Total Knee Replacement Clinical Trial 2023: Group 1 Highlights & Side Effects. Trial Name: NCT05018091 — Phase 4
Group 1 2023 Treatment Timeline for Medical Study. Trial Name: NCT05018091 — Phase 4
~0 spots leftby Jan 2025